Welcome to our dedicated page for Cronos Group SEC filings (Ticker: CRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cronos Group Inc. filings document operating results, governance matters, capital structure and material events for a British Columbia-based cannabis issuer. Form 8-K reports include financial-results releases, material agreements, regulatory disclosures, capital-structure items and changes involving finance leadership or principal accounting responsibilities.
Proxy and shareholder-meeting filings describe director elections, executive compensation votes, auditor appointments, board governance and voting results. The filing record also reflects the company’s public-company reporting framework for its cannabis brand portfolio, including Spinach®, PEACE NATURALS®, LIT® and Lord Jones®, and the governance disclosures associated with its common shares listed under CRON.
Cronos Group Inc. reported routine equity compensation activity by officer Terrence Gregory Joseph Doucet. On May 12, 2026, he exercised 10,597 restricted stock units (RSUs), receiving the same number of common shares at a stated price of $0.00 per share. To cover tax obligations, 5,199 common shares were disposed of at $3.75 per share in a tax-withholding transaction, which the data notes is priced in Canadian dollars. After these transactions, Doucet directly holds 110,588 common shares of Cronos Group. Each RSU represents a contingent right to receive one common share, and the exercised units reflect part of a 31,793 RSU grant that vests in three substantially equal annual installments beginning on the first anniversary of the May 12, 2025 grant date.
Cronos Group Inc. reported that company officer Adam Wagner exercised restricted stock units into common shares. On May 12, 2026, 10,367 restricted stock units vested and converted into 10,367 common shares at no exercise price, increasing his directly held common shares to 103,987. The RSUs each represent a right to receive one Cronos common share, and this transaction reflects the first vesting installment of a 31,102-unit grant awarded on May 12, 2025, which vests in three substantially equal annual installments.
Cronos Group Inc. officer Buggy Shannon reported routine equity compensation activity involving restricted stock units (RSUs). On May 12, 2026, Shannon exercised RSUs to acquire 20,622 common shares, shown as a derivative exercise/conversion at a stated price of $0.00 per share.
To cover tax obligations, 9,179 common shares were disposed of through a tax-withholding transaction at $2.75 per share, rather than through an open-market sale. After these transactions, Shannon directly held 178,322 common shares of Cronos Group Inc.
Cronos Group Inc. officer Jared Matthew Kenost reported routine equity compensation activity. On May 12, 2026, he exercised 9,412 restricted stock units (RSUs) into common shares and had 3,701 common shares withheld at $2.75 per share to cover tax obligations.
Following these transactions, he directly owned 42,974 common shares. In addition, he was granted 30,000 new RSUs that were originally awarded on March 12, 2026 and vest in three substantially equal annual installments, adding to previously granted RSUs from March 12, 2025.
Cronos Group Inc. executive Arye Weigensberg exercised restricted stock units into common shares in a compensation-related move. On May 10, 2026, 3,118 restricted stock units converted into 3,118 common shares at a stated price of $0.00 per share, increasing his direct common share holdings to 211,555 shares. Following the transaction, he also continued to hold 154,419 restricted stock units, each representing a contingent right to receive one common share of Cronos Group Inc.
Cronos Group Inc. officer Adam Wagner reported routine equity compensation activity. On May 10, 2026, he exercised restricted stock units, converting 20,470 RSUs into the same number of common shares at no cash cost. Following these transactions, he directly owns 93,620 common shares. Footnotes explain these RSUs came from prior grants of 30,190 and 31,220 RSUs awarded in 2023 and 2024, each vesting in three substantially equal annual installments, so this filing reflects scheduled vesting rather than open‑market trading.
Cronos Group Inc. officer Jared Matthew Kenost reported routine equity compensation activity. On May 10, 2026, previously granted restricted stock units vested and were exercised into 12,649 common shares. To cover tax obligations, 4,774 common shares were disposed of at $2.54 per share as tax-withholding, not as open-market sales. Following these transactions, he continues to hold a direct equity stake in Cronos common shares.
Cronos Group Inc. reported significantly stronger results for the quarter ended March 31, 2026. Net revenue rose to 45,210 (thousands of U.S. dollars) from 32,262 a year earlier, driven by cannabis flower and extracts in Canada and Israel. Net income attributable to Cronos increased to 13,752, with basic and diluted EPS of 0.04 versus 0.02. Adjusted EBITDA improved to 5,079 from 2,289, reflecting higher gross profit despite ongoing restructuring and transaction costs. The company ended the quarter with 821,856 in cash and cash equivalents and no debt, after repurchasing 6,365,700 common shares for 16,730 under its 50,000 share repurchase authorization. A new 50,000 repurchase program was approved to follow the current one, and Cronos continues to pursue the pending acquisition of CanAdelaar and manage legal and regulatory matters, including a proposed 10,000 class action settlement that remains subject to court approval.
Cronos Group Inc. reported strong first quarter 2026 results, with net revenue rising 40% year-over-year to $45.2 million and net income more than doubling to $15.7 million. Adjusted EBITDA improved to $5.1 million, up 122% from the prior-year period, helped by higher cannabis flower and extract sales in Canada, Israel and other international markets.
The company’s Spinach, PEACE NATURALS, LIT and Lord Jones brands all contributed to growth, including #1 vape share in Canada and continued leadership in Israeli medical cannabis. Cronos ended the quarter with $821.9 million in cash and cash equivalents and authorized a new share repurchase program of up to $50 million running through May 2027. The company also extended the outside date to close its pending acquisition of Dutch producer CanAdelaar B.V. to September 9, 2026 to allow more time for regulatory clearances.
Cronos Group Inc. is holding its 2026 annual meeting of shareholders as a virtual-only event on June 18, 2026 at 11:00 a.m. Eastern time. Shareholders will vote on electing seven directors, advisory “say on pay” and its frequency, and appointing Davidson & Company LLP as independent auditor for 2026.
The meeting will also receive the audited consolidated financial statements for the year ended December 31, 2025. Shareholders of record at 5:00 p.m. Eastern time on April 23, 2026, when 376,271,333 common shares were outstanding, are entitled to vote online, by telephone, Internet or mail.